行情

ACRX

ACRX

AcelRx制药
NASDAQ

实时行情|Nasdaq Last Sale

1.900
-0.090
-4.52%
盘后: 1.900 0 0.00% 18:55 01/17 EST
开盘
2.000
昨收
1.990
最高
2.000
最低
1.900
成交量
68.72万
成交额
--
52周最高
4.090
52周最低
1.640
市值
1.51亿
市盈率(TTM)
-2.8418
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACRX 新闻

  • 软银秘密投资配送创企GoPuff 7.5亿美元
  • 猎云网.3小时前
  • 英媒:美打压华为损害欧洲电信业 对手也无法受益
  • 参考消息.4小时前
  • 特斯拉存在意外加速隐患 或波及50万辆汽车
  • 36氪.4小时前
  • 奥美要在美国裁员约80人 包括首席创意官
  • 界面.5小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ACRX 简况

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
展开

Webull提供AcelRx Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。